News Breaks |
|
|
| April 20, 2012 |
| 05:52 EDT |  | NVS | Novartis confirms positive benefit-risk profile of Gilenya following CHMP review
Novartis announced that the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has confirmed a positive benefit-risk profile of once-daily oral Gilenya, or ingolimod. Novartis and the CHMP have agreed to recommended updates to the product information in the European Union in order to provide further guidance to healthcare providers regarding treatment initiation with Gilenya in MS patients. The changes follow the Article 20 review by the EMA announced in January 2012. |
|
|
News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. |
|
|
| May 24, 2013 |
| 08:22 EDT |  | NVS | Leerink's biotech analysts hold an analyst/industry conference call
 Subscribe for More Information |
|
| May 21, 2013 |
| 07:44 EDT | | NVS | Sachs Associates to host a forum
Subscribe for More Information |
|
| 07:24 EDT | | NVS | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 07:29 EDT | | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. |
|
| May 17, 2013 |
| 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
Subscribe for More Information |
|
| May 16, 2013 |
| 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
|
|
|
|
|
